Overview

Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer

Status:
Completed

Trial end date:
2016-03-01

Target enrollment:

Participant gender:

Summary

This is a randomized, Phase II, double-blind, multicenter, placebo-controlled trial designed to preliminarily estimate the efficacy and evaluate the safety and tolerability of onartuzumab (MetMAb) + bevacizumab + paclitaxel and onartuzumab + placebo + paclitaxel versus placebo + bevacizumab + paclitaxel in participants with metastatic or locally recurrent, triple-negative breast cancer who either have not received treatment (first-line) or have progressed after one conventional cytotoxic chemotherapy regimen (second-line).

Phase:

Phase 2

Details

Lead Sponsor:

Genentech, Inc.

Collaborator:

Hoffmann-La Roche

Treatments:

Albumin-Bound Paclitaxel
Antibodies, Monoclonal
Bevacizumab
Paclitaxel